Bioengineering of lanthipeptides in Escherichia coli: Assessing the specificity of lichenicidin and haloduracin biosynthetic machinery

Research in Microbiology

Volumn 165, Issue 7, 2014, Pages 600-604

  Caetano, T ^a   Barbosa, J ^a   Moesker E ^b   Sussmuth R D ^b   Mendo, S ^a  

^a UNIVERSITY OF AVEIRO   (Portugal)

^b TECHNISCHE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Bacillus; Bacteriocins; Chimeras; Invivo; Lantibiotics

Indexed keywords

HALODURACIN; LACTICIN 481; LANTIBIOTIC; LICHENICIDIN; NUKACIN ISK 1; SIGNAL PEPTIDE; UNCLASSIFIED DRUG; BACTERIOCIN; HALODURACIN, BACILLUS HALODURANS; LICHENICIDIN, BACILLUS LICHENIFORMIS; RECOMBINANT PROTEIN;

ARTICLE; CHIMERA; ENZYME ACTIVITY; ESCHERICHIA COLI; GENE CLUSTER; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; STRUCTURAL GENE; BIOSYNTHESIS; ENZYME SPECIFICITY; GENETICS; METABOLIC ENGINEERING; METABOLISM;

ESCHERICHIA COLI;

BACTERIOCINS; BIOSYNTHETIC PATHWAYS; ESCHERICHIA COLI; METABOLIC ENGINEERING; RECOMBINANT PROTEINS; SUBSTRATE SPECIFICITY;

EID: 84926416661     PISSN: 09232508     EISSN: 17697123     Source Type: Journal    
DOI: 10.1016/j.resmic.2014.07.006     Document Type: Article

References (25)

1. Arnison P.G., Bibb M.J., Bierbaum G., Bowers A.A., Bugni T.S., Bulaj G., et al. Ribosomally synthesized and post-translationally modified peptide natural products: overview and recommendations for a universal nomenclature. Nat Prod Rep 2013, 30:108-160. Available from:. http://www.ncbi.nlm.nih.gov/pubmed/23165928.
2. Asaduzzaman S.M., Sonomoto K. Lantibiotics: diverse activities and unique modes of action. J Biosci Bioeng 2009, 107:475-487.
3. Yoganathan S., Vederas J.C. Fracturing rings to understand lantibiotics. Chem Biol 2008, 15:999-1001. 10.1016/j.chembiol.2008.10.001.
4. Prieto M.L., O'Sullivan L., Tan S.P., McLoughlin P., Hughes H., O'Connor P.M., et al. Assessment of the bacteriocinogenic potential of marine bacteria reveals lichenicidin production by seaweed-derived Bacillus spp. Mar Drugs 2012, 10:2280-2299. 10.3390/md10102280.
5. Field D., Connor P.M.O., Cotter P.D., Hill C., Ross R.P. The generation of nisin variants with enhanced activity against specific gram-positive pathogens. Mol Microbiol 2008, 69:218-230. Available from:. http://www.ncbi.nlm.nih.gov/pubmed/18485077.
6. Field D., Hill C., Cotter P.D., Ross R.P. The dawning of a "Golden era" in lantibiotic bioengineering. Mol Microbiol 2010, 78:1077-1087. Available from:. http://www.ncbi.nlm.nih.gov/pubmed/21091497.
7. Li B., Sher D., Kelly L., Shi Y., Huang K., Knerr P.J., et al. Catalytic promiscuity in the biosynthesis of cyclic peptide secondary metabolites in planktonic marine cyanobacteria. Proc Natl Acad Sci U S A 2010, 107:10430-10435. 10.1073/pnas.0913677107.
8. Nagao J., Aso Y., Shioya K., Nakayama J., Sonomoto K. Lantibiotic engineering: molecular characterization and exploitation of lantibiotic-synthesizing enzymes for peptide engineering. J Mol Microbiol Biotechnol 2007, 13:235-242. 10.1159/000104749.
9. Krawczyk B., Ensle P., Müller W.M., Süssmuth R.D. Deuterium labeled peptides give insights into the directionality of class III lantibiotic synthetase LabKC. J Am Chem Soc 2012, 134:9922-9925. Available from:. http://dx.doi.org/10.1021/ja3040224.
10. Krawczyk J.M., Völler G.H., Krawczyk B., Kretz J., Brönstrup M., Süssmuth R.D. Heterologous expression and engineering studies of labyrinthopeptins, class III lantibiotics from actinomadura namibiensis. Chem Biol 2013, 20:111-122. Available:. http://www.sciencedirect.com/science/article/pii/S1074552112004279.
11. Dischinger J., Josten M., Szekat C., Sahl H.-G., Bierbaum G. Production of the novel two-peptide lantibiotic lichenicidin by Bacillus licheniformis DSM 13. PLoS One 2009, 4:e6788. Available from:. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2727956%26tool=pmcentrez%26rendertype=abstract.
12. Shenkarev Z.O., Finkina E.I., Nurmukhamedova E.K., Balandin S.V., Mineev K.S., Nadezhdin K.D., et al. Isolation, structure elucidation, and synergistic antibacterial activity of a novel two-component lantibiotic lichenicidin from Bacillus licheniformis VK21. Biochemistry 2010, 49:6462-6472. Available from:. http://www.ncbi.nlm.nih.gov/pubmed/20578714.
13. Caetano T., Krawczyk J.M., Mösker E., Süssmuth R.D., Mendo S. Heterologous expression, biosynthesis, and mutagenesis of type II lantibiotics from Bacillus licheniformis in Escherichia coli. Chem Biol 2011, 18:90-100. Available from:. http://www.ncbi.nlm.nih.gov/pubmed/21276942.
14. Oldach F., Al Toma R., Kuthning A., Caetano T., Mendo S., Budisa N., et al. Congeneric lantibiotics from ribosomal invivo peptide synthesis with noncanonical amino acids. Angew Chem Int Ed Engl 2012, 51:415-418. 10.1002/anie.201106154.
15. McClerren A.L., Cooper L.E., Quan C., Thomas P.M., Kelleher N.L., van der Donk W.A. Discovery and invitro biosynthesis of haloduracin, a two-component lantibiotic. Proc Natl Acad Sci U S A 2006, 103:17243-17248. 10.1073/pnas.0606088103.
16. Lawton E.M., Cotter P.D., Hill C., Ross R.P. Identification of a novel two-peptide lantibiotic, haloduracin, produced by the alkaliphile Bacillus halodurans C-125. FEMS Microbiol Lett 2007, 267:64-71. 10.1111/j.1574-6968.2006.00539.x.
17. Caetano T., Krawczyk J.M., Mösker E., Süssmuth R.D., Mendo S. Lichenicidin biosynthesis in Escherichia coli: licFGEHI immunity genes are not essential for lantibiotic production or self-protection. Appl Environ Microbiol 2011, 77:5023-5026. Available from:. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3147384%26tool=pmcentrez%26rendertype=abstract.
18. Shi Y., Yang X., Garg N., van der Donk W.A. Production of lantipeptides in Escherichia coli. J Am Chem Soc 2010, 133:2338-2341. Available from:. http://dx.doi.org/10.1021/ja109044r.
19. Knerr P.J., van der Donk W.A. Discovery, biosynthesis, and engineering of lantipeptides. Annu Rev Biochem 2012, 81:479-505. Available from:. http://www.ncbi.nlm.nih.gov/pubmed/22404629.
20. Kuipers A., Meijer-Wierenga J., Rink R., Kluskens L.D., Moll G.N. Mechanistic dissection of the enzyme complexes involved in biosynthesis of lacticin 3147 and nisin. Appl Environ Microbiol 2008, 74:6591-6597. 10.1128/AEM.01334-08.
21. Furgerson Ihnken L.A., Chatterjee C., van der Donk W.A. Invitro reconstitution and substrate specificity of a lantibiotic protease. Biochemistry 2008, 47:7352-7363. 10.1021/bi800278n.
22. Levengood M.R., Patton G.C., van der Donk W.A. The leader peptide is not required for post-translational modification by lacticin 481 synthetase. J Am Chem Soc 2007, 129:10314-10315. Available from:. http://dx.doi.org/10.1021/ja072967+.
23. Patton G.C., Paul M., Cooper L.E., Chatterjee C., van der Donk W.A. The importance of the leader sequence for directing lanthionine formation in lacticin 481. Biochemistry 2008, 47:7342-7351. 10.1021/bi800277d.
24. Chatterjee C., Patton G.C., Cooper L., Paul M., van der Donk W.A. Engineering dehydro amino acids and thioethers into peptides using lacticin 481 synthetase. Chem Biol 2006, 13:1109-1117. Available from:. http://www.sciencedirect.com/science/article/pii/S1074552106003395.
25. Majchrzykiewicz J.A., Lubelski J., Moll G.N., Kuipers A., Bijlsma J.J.E., Kuipers O.P., et al. Production of a class ii two-component lantibiotic of Streptococcus pneumoniae using the class I nisin synthetic machinery andleader sequence. Antimicrobial Agents Chemother 2010, 54:1498-1505. Available from:. http://aac.asm.org/content/54/4/1498.abstract.